Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation

scientific article published on 14 April 2020

Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/S41409-020-0887-4
P932PMC publication ID7483973
P698PubMed publication ID32286506

P50authorSergio GiraltQ66764444
Edward A. StadtmauerQ85544110
Luciano J CostaQ88251235
P2093author name stringElizabeth E Brown
Amrita Y Krishnan
Parameswaran Hari
Francesca Patriarca
Andrea Evangelista
Benedetto Bruno
Marcelo C Pasquini
Gösta Gahrton
Riddhi Modi
Joan Blade
Luisa Giaccone
Simona Iacobelli
Jose A Perez-Simon
Laura Rosinol
Stefan Schonland
P2860cites workToxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patientsQ33402680
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.Q34241661
International staging system for multiple myelomaQ34408882
A comparison of allografting with autografting for newly diagnosed myelomaQ34577703
Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant researchQ35031141
Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myelomaQ35651684
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trialQ36725446
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working GroupQ36839385
Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation.Q37282307
Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignmentQ38042273
Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcomeQ40752336
Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.Q44616173
Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.Q45361447
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.Q46907944
Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse SurvivalQ47566330
Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma.Q49504538
Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study.Q51395943
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma.Q52912068
Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centresQ57904065
Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myelomaQ61803948
Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow TransplantationQ68016829
Graft-versus-myeloma effectQ71264400
The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myelomaQ76376753
Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myelomaQ79696686
Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocolQ81168226
A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myelomaQ81606574
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myelomaQ82192536
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 TrialQ84401841
Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-upQ84509627
Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple MyelomaQ88528165
Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 TrialQ91397924
P577publication date2020-04-14
P1433published inBone Marrow TransplantationQ4941523
P1476titleLong-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation

Reverse relations

Q97866962Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMTcites workP2860

Search more.